drugset / Trial / NCT05107778
Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis B virus. The study is aimed at evaluating efficacy and safety of ASC42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic hepatitis B virus.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2023-11-14
- Completion
- 2023-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASC42 | Unknown | 10 mg | Oral |
| Subject | ASC42 | Unknown | 15 mg | Oral |
| Background | Entecavir | Small molecule | 0.5 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |